Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.

May 09, 2025

Vol.51 No.18

Clinical

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

Pfizer Inc. on April 26 announced results from the pivotal phase III CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard-of-care Bacillus Calmette-Guérin as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Johnson & Johnson on April 26 announced new data from cohort 2 of the pivotal phase IIB SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

Zongertinib, a human epidermal growth factor receptor 2 targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated non-small cell lung cancer that harbored a HER2 mutation, according to results from the phase IA/IB Beamion LUNG-1 trial.

May 02, 2025

Vol.51 No.17

Cancer Policy

HHS said it would terminate Women’s Health Initiative, then reconsidered

On April 21, Women’s Health Initiative investigators were informed that HHS would be terminating the WHI Regional Center contracts at the end of the current fiscal year.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb and Claire Marie Porter

Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores

YOU MAY BE INTERESTED IN

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

HHS said it would terminate Women’s Health Initiative, then reconsidered

Renew today!

Subscriber content

Never miss an issue!

Login

Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores

YOU MAY BE INTERESTED IN

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

HHS said it would terminate Women’s Health Initiative, then reconsidered

Never miss an issue!

Login

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child